Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics is a company with strong potential for growth in their plasma and hospital segments, driven by demand for their products and solutions in blood and plasma collection and hospital transfusion services. While the company has faced challenges in its interventional technologies segment, management remains confident in their efforts to improve this area. Financially, the company has a strong cash position and is focused on reducing debt and achieving their target operating margin, which could drive increased profitability in the future. With the positive outlook for the healthcare industry and the company's optimistic outlook for future innovations and label expansion in Europe, Haemonetics is expected to perform well and is rated OUTPERFORM with a target price of $94.

Haemonetics is facing significant headwinds in the competitive blood center segment, as well as challenges in its interventional technologies business. While its plasma and hospital segments show potential for growth, the company's overall revenue and gross margins have been impacted by tariffs and the absence of prior year CSL payments. Despite a focus on cost control, operating expenses remain high, leading to a slight miss on adjusted EPS in the most recent quarter. The company's initial FY/27 financial guidance also suggests a lower-than-expected non-GAAP EPS growth. This, coupled with risks such as potential M&A and cybersecurity, contributes to a negative outlook for Haemonetics' stock.